![LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases](https://www.seventure.fr/wp-content/uploads/2020/07/10_104270789-322x211.jpg)
9 September 2020
LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases
LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, today announced that...